Is amyloid β-protein glycated in Alzheimerʼs disease?
- 1 March 1997
- journal article
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 8 (4) , 907-909
- https://doi.org/10.1097/00001756-199703030-00018
Abstract
Recent data suggest that protein glycation is involved in the process of amyloid formation in Alzheimer's disease (AD). To further investigate this issue, we analyzed the presence of advanced glycation end products (AGE) in soluble and insoluble forms of amyloid beta-protein (A beta) as well as in apolipoprotein E (apoE), a protein bound to amyloid deposits. Both proteins were extracted from cerebral cortex obtained from patients with AD and probed by immunoblotting with two antibodies specific for different AGE, already known to immunocytochemically label amyloid plaques. All the AGE antibodies failed to recognize either A beta or apoE, whereas they reacted with synthetic A beta glycated in vitro. These findings indicate that other proteins associated with amyloid deposits are candidates to be modified with AGE in Alzheimer's cerebral tissue.Keywords
This publication has 5 references indexed in Scilit:
- Diabetes mellitus and Alzheimer's disease: glycation as a biochemical linkDiabetologia, 1996
- Apolipoprotein E in animal models of CNS injury and in alzheimer's diseaseTrends in Neurosciences, 1994
- Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline.Journal of Clinical Investigation, 1992
- The molecular pathology of Alzheimer's diseaseNeuron, 1991
- Nonenzymatic Browning in Vivo: Possible Process for Aging of Long-Lived ProteinsScience, 1981